ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 124 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,000 | -99.9% | 628 | -100.0% | 0.00% | -100.0% |
| Q3 2019 | $5,616,000 | +40.4% | 1,560,009 | +4.5% | 0.03% | +44.4% |
| Q2 2019 | $3,999,000 | +18.1% | 1,492,489 | +30.4% | 0.02% | +20.0% |
| Q1 2019 | $3,387,000 | +136.0% | 1,144,325 | +26.7% | 0.02% | +114.3% |
| Q4 2018 | $1,435,000 | -58.7% | 902,840 | -4.4% | 0.01% | -46.2% |
| Q3 2018 | $3,474,000 | -0.9% | 944,191 | -23.8% | 0.01% | -7.1% |
| Q2 2018 | $3,505,000 | +178.2% | 1,238,820 | +264.7% | 0.01% | +180.0% |
| Q1 2018 | $1,260,000 | -4.4% | 339,718 | -25.8% | 0.01% | 0.0% |
| Q4 2017 | $1,318,000 | +862.0% | 457,713 | +1403.6% | 0.01% | +400.0% |
| Q3 2017 | $137,000 | +328.1% | 30,442 | +336.3% | 0.00% | – |
| Q2 2017 | $32,000 | +52.4% | 6,978 | +254.4% | 0.00% | – |
| Q4 2015 | $21,000 | -40.0% | 1,969 | -61.2% | 0.00% | – |
| Q3 2015 | $35,000 | +34.6% | 5,073 | +69.7% | 0.00% | – |
| Q2 2015 | $26,000 | – | 2,989 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 13,633,220 | $57,396,000 | 7.04% |
| HealthInvest Partners AB | 497,807 | $2,096,000 | 3.21% |
| BVF INC/IL | 3,285,400 | $13,832,000 | 2.35% |
| EMORY UNIVERSITY | 486,438 | $2,048,000 | 1.93% |
| Marcus Capital, LLC | 69,400 | $1,751,000 | 1.63% |
| DAFNA Capital Management LLC | 196,500 | $827,000 | 0.70% |
| Orbimed Advisors | 13,107,200 | $55,181,000 | 0.62% |
| Rock Springs Capital Management LP | 1,500,000 | $6,315,000 | 0.36% |
| Spark Investment Management LLC | 710,100 | $2,989,000 | 0.19% |
| TURNER INVESTMENTS LLC | 65,420 | $275,000 | 0.18% |